Skip to content

Telmisartan

Micardis, Kinzalmono, Pritor, Telmisartan Boehringer Ingelheim Pharma KG (telmisartan) is a small molecule pharmaceutical. Telmisartan was first approved as Micardis on 1998-11-10. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. It has been approved in Europe to treat hypertension. The pharmaceutical is active against type-1 angiotensin II receptor. In addition, it is known to target peroxisome proliferator-activated receptor gamma. Micardis's patent is valid until 2022-10-06 (FDA).
Trade Name Kinzalmono, Micardis, Pritor, Telmisartan Boehringer Ingelheim Pharma KG
Common Name Telmisartan
Indication diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction
Drug Class Angiotensin II receptor antagonists
Telmisartan
Get full access now